AAPL,Apple loses patent retrial to VirnetX, owes $302.4 million NEW YORK, Sept. 30 A federal jury in Texas on Friday night ordered Apple Inc to pay more than $302 million in damages for using VirnetX Holding Corp's patented internet security technology without permission in features including its FaceTime video conferencing application. 
JNJ,Novartis psoriasis drug maintains efficacy after 4 years - studyNovartis psoriasis drug maintains efficacy after four years: studyMorphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.  Morphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab. ZURICH Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.Morphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.   Novartis psoriasis drug maintains efficacy after four years: studyMorphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.  Morphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab. ZURICH Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.Morphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.  ZURICH, Oct 1 Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson .Novartis psoriasis drug maintains efficacy after four years: studyMorphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.  Morphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab. ZURICH Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson.Morphosys moves closer to getting first antibody drug on market FRANKFURT, Oct 1 German biotech Morphosys  moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit  Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab.   
